Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV

The integrase inhibitor dolutegravir was included in initial antiretroviral therapy in Brazil in January 2017. Studies have demonstrated that the efficacy and safety of antiretrovirals have improved with the introduction of new classes of antiretrovirals, such as integrase inhibitors. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Correa, Analú, Monteiro, Polyana, Calixto, Fernanda, Batista, Joanna d’Arc Lyra, de Alencar Ximenes, Ricardo Arraes, Montarroyos, Ulisses Ramos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458288/
https://www.ncbi.nlm.nih.gov/pubmed/32866163
http://dx.doi.org/10.1371/journal.pone.0238052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458288/
https://www.ncbi.nlm.nih.gov/pubmed/32866163
http://dx.doi.org/10.1371/journal.pone.0238052

Ejemplares similares